The Nordic countries join forces in HTA medicine assessments
The aim of the cooperation is to harmonize processes and produce joint assessments that each country can use in its own decision-making.
Medaffcon’s Patient Dynamics tool compiles up-to-date and regional data on medicine use in Finland and, more recently, also in Sweden. The tool has been in use for about two years, and Medaffcon continues to develop it to provide pharmaceutical companies with even more precise data.
According to Medaffcon’s Market Access Manager, Timo Karvinen, the tool now makes it possible to access information by medical specialty and by prescriber. Rare disease medicines have also been included, and patient types have been defined. Reports, for example, can show which other medicines are used simultaneously with a particular drug. Cost information can also be incorporated into the analyses.
“The number of therapy areas has expanded, and rare disease medicines and special cases have now been included. That’s where our expertise has been particularly valuable – we have been able to provide solutions for more complex cases,” Karvinen explains.
“Our goal is to obtain data on a health care unit level and to be able to examine treatment lines further than we currently can. We want to reach an even deeper level of information,” he adds.
The data is based on purchases of reimbursed medicines registered with Kela (the Finnish Social Insurance Institution) and is now available both nationwide and regionally. This enables precise allocation of resources to the right areas.
Patient Dynamics was created in response to the need for more detailed data on medicine use to support sales and marketing. The tool is particularly valuable for the launch of new medicines or indications but is also used in monitoring established products. It complements sales data by providing insights into, for example, patient numbers and the use of competitors’ products.
Medaffcon works closely with its customers and is transparent about the sources of the data and how the results are derived. Customers also have the option of receiving a comprehensive Excel dashboard for in-depth data analysis. In addition, key analyses can be delivered as a PowerPoint summary.
The aim of the cooperation is to harmonize processes and produce joint assessments that each country can use in its own decision-making.
Access times to medicines vary greatly between European countries, and delays in oncology drugs in particular are increasing.
Finland is developing a model to streamline the adoption of digital healthcare solutions.
Market Access Manager
MSc (Food Science)
Timo started at Medaffcon in May 2023, bringing his experience and know-how e.g. about developing and utilizing analyses. Timo’s long experience in pharma industry in analytics, marketing and sales gives him a good understanding of the operation of pharmaceutical companies. Timo holds a MSc in Food Economics and Marketing. Market Access and Health economic analyses are new development areas for Timo. In his previous role Timo developed analytical services for pharmaceutical companies.
Timo is inspired about supporting and helping decision making with data. “Data provides a solid foundation for decisions. Data acquired and analyses carried out should be grounded on the decisions made based on them.” Developing new things and overcoming challenges gives Timo energy at work.
Timo believes, that in the future data will be collected and combined from more sources than before. Evaluating effectiveness will be important in decision making in health care and more comprehensive health economic analyses will be needed.